Skip to main content
SpringerLink
Log in

Intraoperative Brachytherapy for Resected Brain Metastases

  • Chapter
  • First Online:
Central Nervous System Metastases

  • 628 Accesses

Abstract

Brain metastases are the most common intracranial malignancies in adults. Surgical resection is the preferred treatment approach when a pathological diagnosis is required or for large symptomatic lesions. Radiotherapy is administered to improve local control rates following surgical resection. After a brief review of the literature describing the treatment of brain metastases using whole brain radiotherapy, postoperative stereotactic radiosurgery, preoperative radiosurgery, and intraoperative interstitial and intracavitary brachytherapy, we center our discussion on comparing the patient-related, technical, practical, and radiobiological considerations of each technique. Finally, we focus on the rationale, technique, evidence, and future directions regarding intraoperative brachytherapy as an underutilized technique with promising outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14.

    Article  PubMed  Google Scholar 

  2. Nichols EM, Patchell RA, Regine WF, Kowk Y. Palliation of the brain and spinal cord metastases. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady’s principles of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1765–72.

    Google Scholar 

  3. Delattre JY, Krol G, Thaler HT, et al. Distribution of brain metastases. Arch Neurol. 1988;45:741–4.

    Article  CAS  PubMed  Google Scholar 

  4. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5):352–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, Morgan S, Lee C, Waite K, Bayman N, Pugh C, Sydes B, Stephens R, Parmar MK, Langley RE. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  7. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.

    Article  CAS  PubMed  Google Scholar 

  8. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA. 1998;280(17):1485–9.

    Article  CAS  PubMed  Google Scholar 

  9. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.

    Article  PubMed  Google Scholar 

  10. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. JAMA. 2006;295(21):2483–91.

    Article  CAS  PubMed  Google Scholar 

  11. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.

    Article  PubMed  Google Scholar 

  12. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 Study. J Clin Oncol. 2011;29(2):134–41.

    Article  PubMed  Google Scholar 

  13. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases. JAMA. 2016;316(4):401–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65–72.

    Article  PubMed  Google Scholar 

  15. Yamamoto M, Serizawa T, Shuto T. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–95.

    Article  PubMed  Google Scholar 

  16. NCCN Guidelines Version 1.2018 Central Nervous System Cancers, https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 6 May 2020.

  17. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Roberge D, Parney I, Brown PD. Radiosurgery to the postoperative surgical cavity: who needs evidence? Int J Radiat Oncol Biol Phys. 2012;83(2):486–93.

    Article  PubMed  Google Scholar 

  19. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–60.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Patel KR, Burri SH, Asher AL, et al. Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases. Neurosurgery. 2016;79(2):279–85.

    Article  PubMed  Google Scholar 

  21. Asher AL, Burri SH, Wiggins WF, Kelly RP, Boltes MO, Mehrlich M, Norton HJ, Fraser RW. A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. Int J Radiat Oncol Biol Phys. 2014;88(4):899–906.

    Article  PubMed  Google Scholar 

  22. Soltys SG, Adler JR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2008;70(1):187–93.

    Article  PubMed  Google Scholar 

  23. Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys. 2012;84(2):336–42.

    Article  PubMed  Google Scholar 

  24. Atalar B, Choi CY, Harsh GR, et al. Cavity volume dynamics after resection of brain metastases and timing of postresection cavity stereotactic radiosurgery. Neurosurgery. 2013;72(2):180–5; discussion 185.

    Article  PubMed  Google Scholar 

  25. Jarvis LA, Simmons NE, Bellerive M, et al. Tumor bed dynamics after surgical resection of brain metastases: implications for postoperative radiosurgery. Int J Radiat Oncol Biol Phys. 2012;84(4):943–8.

    Article  PubMed  Google Scholar 

  26. Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88(1):130–6.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Prabhu R, Shu HK, Hadjipanayis C, et al. Current dosing paradigm for stereotactic radiosurgery alone after surgical resection of brain metastases needs to be optimized for improved local control. Int J Radiat Oncol Biol Phys. 2012;83(1):e61–6.

    Article  PubMed  Google Scholar 

  28. Seymour ZA, Fogh SE, Westcott SK, Braunstein S, Larson DA, Barani IJ, Nakamura J, Sneed PK. Interval from imaging to treatment delivery in the radiation surgery age: how long is too long? Int J Radiat Oncol Biol Phys. 2015;93(1):126–32.

    Article  PubMed  Google Scholar 

  29. Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol. 1994;66(5):427–32.

    Article  CAS  PubMed  Google Scholar 

  30. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291–8.

    Article  CAS  PubMed  Google Scholar 

  31. Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2010;77(4):996–1001.

    Article  PubMed  Google Scholar 

  32. Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011;6(1):48.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sneed PK, Mendez J, Vemer-van den Hoek JG, et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg. 2015;123(2):373–86.

    Article  CAS  PubMed  Google Scholar 

  34. Bernstein M, Cabantog A, Laperriere N, Leung P, Thomason C. Brachytherapy for recurrent single brain metastasis. Can J Neurol Sci. 1995;22(1):13–6.

    Article  CAS  PubMed  Google Scholar 

  35. Bogart JA, Ungureanu C, Shihadeh E, Chung TC, King GA, Ryu S, Kent C, Winfield JA. Resection and permanent I-125 brachytherapy without whole brain irradiation for solitary brain metastasis from non-small cell lung carcinoma. J Neurooncol. 1999;44(1):53–7.

    Article  CAS  PubMed  Google Scholar 

  36. Dagnew E, Kanski J, McDermott MW, Sneed PK, McPherson C, Breneman JC, Warnick RE. Management of newly diagnosed single brain metastasis using resection and permanent iodine-125 seeds without initial whole-brain radiotherapy: a two institution experience. Neurosurg Focus. 2007;22(3):E3.

    Article  PubMed  Google Scholar 

  37. Huang K, Sneed PK, Kunwar S, Kragten A, Larson DA, Berger MS, Chan A, Pouliot J, McDermott MW. Surgical resection and permanent iodine-125 brachytherapy for brain metastases. J Neurooncol. 2009;91(1):83–93.

    Article  CAS  PubMed  Google Scholar 

  38. Ostertag CB, Kreth FW. Interstitial iodine-125 radiosurgery for cerebral metastases. Br J Neurosurg. 1995;9(5):593–603.

    Article  CAS  PubMed  Google Scholar 

  39. Schulder M, Black PM, Shrieve DC, Alexander E 3rd, Loeffler JS. Permanent low-activity iodine-125 implants for cerebral metastases. J Neurooncol. 1997;33(3):213–21.

    Article  CAS  PubMed  Google Scholar 

  40. Limbrick DD Jr, Lusis EA, Chicoine MR, Rich KM, Dacey RG, Dowling JL, et al. Combined surgical resection and stereotactic radiosurgery for treatment of cerebral metastases. Surg Neurol. 2009;71:280–8.

    Article  PubMed  Google Scholar 

  41. Mathieu D, Kondziolka D, Flickinger JC, Fortin D, Kenny B, Michaud K, et al. Tumor bed radiosurgery after resection of cerebral metastases. Neurosurgery. 2008;62:817–23.

    Article  PubMed  Google Scholar 

  42. Wegner RE, Leeman JE, Kabolizadeh P, Rwigema JC, Mintz AH, Burton SA, et al. Fractionated stereotactic radiosurgeryfor large brain metastases. Am J Clin Oncol. 2015;38:135–9.

    Article  PubMed  Google Scholar 

  43. Wernicke AG, Hirschfeld CB, Smith AW, Taube S, Yondorf MZ, Parashar B, Nedialkova L, Kulidzhanov F, Trichter S, Sabbas A, Ramakrishna R, Pannullo S, Schwartz TH. Clinical outcomes of large brain metastases treated with neurosurgical resection and intraoperative Cesium-131 brachytherapy: results of a prospective trial. Int J Radiat Oncol Biol Phys. 2017;98(5):1059–68.

    Article  PubMed  Google Scholar 

  44. Choi CY, Chang SD, Gibbs IC, et al. What is the optimal treatment of large brain metastases? An argument for a multidisciplinary approach. Int J Radiat Oncol Biol Phys. 2012;84:688–93.

    Article  PubMed  Google Scholar 

  45. Lee CC, Yen CP, Xu Z, et al. Large intracranial metastatic tumors treated by Gamma Knife surgery: outcomes and prognostic factors. J Neurosurg. 2014;120:52–9.

    Article  PubMed  Google Scholar 

  46. Baschnagel AM, Meyer KD, Chen PY, et al. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. J Neurosurg. 2013 Nov;119:1139–44.

    Article  PubMed  Google Scholar 

  47. Sheehan JP, Sun MH, Kondziolka D, et al. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg. 2002;97(6):1276–81.

    Article  PubMed  Google Scholar 

  48. Ebner D, Rava P, Gorovets D, Cielo D, Hepel JT. Stereotactic radiosurgery for large brain metastases. J Clin Neurosci. 2015;22(10):1650–4.

    Article  PubMed  Google Scholar 

  49. Shrieve DC, Alexander E 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36:275–84.

    Article  CAS  PubMed  Google Scholar 

  50. Knox SJ, Sutherland W, Goris ML. Correlation of tumor sensitivityto low-dose-rate irradiation with G2/M-phase bloc and other radiobiological parameters [Erratum appears in Radiat Res 1993; 136:439]. Radiat Res. 1993;135:24–31.

    Article  CAS  PubMed  Google Scholar 

  51. Rutigliano MJ, Lunsford LD, Kondziolka D, Strauss MJ, Khanna V, Green M. The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors. Neurosurgery. 1995;37:445–55.

    Article  CAS  PubMed  Google Scholar 

  52. Mehta M, Noyes W, Craig B, Lamond J, Auchter R, French M, Johnson M, Levin A, Badie B, Robbins I, Kinsella T. A cost-effectiveness and cost-utility analysis of radiosurgery versus resection for single-brain metastases. Int J Radiat Oncol Biol Phys. 1997;39:445–54.

    Article  CAS  PubMed  Google Scholar 

  53. Lee WY, Cho DY, Lee HC, Chuang HC, Chen CC, Liu JL, Yang SN, Liang JA, Ho LH. Outcomes and cost-effectiveness of gamma knife radiosurgery and whole brain radiotherapy for multiple metastatic brain tumors. J Clin Neurosci. 2009;16:630–4.

    Article  PubMed  Google Scholar 

  54. Wernicke AG, Yondorf MZ, Parashar B, Nori D, Clifford Chao KS, Boockvar JA, Pannullo S, Stieg P, Schwartz TH. The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors. J Neurooncol. 2016;127(1):145–53.

    Article  CAS  PubMed  Google Scholar 

  55. Sneed PK, Lamborn KR, Larson DA, et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1996;35:37–44.

    Article  CAS  PubMed  Google Scholar 

  56. McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol. 1998;14(1):79–87.

    Article  CAS  PubMed  Google Scholar 

  57. Halligan JB, Stelzer KJ, Rostomily RC, et al. Operation and permanent low activity 125I brachytherapy for recurrent high grade astrocytomas. Int J Radiat Oncol Biol Phys. 1996;35:541–7.

    Article  CAS  PubMed  Google Scholar 

  58. Schulz RJ, Chandra P, Nath R. Determination of the exposure rate constant for 125I using a scintillation detector. Med Phys. 1980;7:355–61.

    Article  CAS  PubMed  Google Scholar 

  59. Prados M, Leibel S, Barnett CM, Gutin P. Interstitial brachytherapy for metastatic brain tumors. Cancer. 1989;63(4):657–60.

    Article  CAS  PubMed  Google Scholar 

  60. Petr MJ, McPherson CM, Breneman JC, Warnick RE. Management of newly diagnosed single brain metastasis with surgical resection and permanent I-125 seeds without upfront whole brain radiotherapy. J Neurooncol. 2009;92(3):393–400.

    Article  PubMed  Google Scholar 

  61. Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, MW MD. Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis. J Neurosurg. 2017;126:1749–55.

    Article  CAS  PubMed  Google Scholar 

  62. Yang R, Wang J, Zhang H. Dosimetric study of CS-131, I-125 and Pd-103 seeds for permanent prostate brachytherapy. Cancer Biother Radiopharm. 2009;24:701–5.

    Article  CAS  PubMed  Google Scholar 

  63. Wernicke AG, Yondorf MZ, Peng L, Trichter S, Nedialkova L, Sabbas A, Kulidzhanov F, Parashar B, Nori D, Clifford Chao KS, Christos P, Kovanlikaya I, Pannullo S, Boockvar JA, Stieg PE, Schwartz TH. Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J Neurosurg. 2014;121(2):338–48.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Dale RG, Jones B, Coles IP. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants. Br J Radiol. 1994;67(799):639–45.

    Article  CAS  PubMed  Google Scholar 

  65. Dale RG, Jones B. Enhanced normal tissue doses caused by tumor shrinkage during brachytherapy. Br J Radiol. 1999;72(857):499–501.

    Article  CAS  PubMed  Google Scholar 

  66. Wernicke AG, Lazow SP, Taube S, Yondorf MZ, Kovanlikaya I, Nori D, Christos P, Boockvar JA, Pannullo S, Stieg PE, Schwartz TH. Surgical technique and clinically relevant resection cavity dynamics following implantation of cesium-131 (Cs-131) brachytherapy in patients with brain metastases. Oper Neurosurg. 2016;12(1):49–60.

    Article  Google Scholar 

  67. Pham A, Yondorf MZ, Parashar B, Scheff RJ, Pannullo SC, Ramakrishna R, Stieg PE, Schwartz TH, Wernicke AG. Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial. J Neurooncol. 2016;127(1):63–71.

    Article  CAS  PubMed  Google Scholar 

  68. Yondorf M, Schwartz T, Boockvar J, Pannullo S, Stieg P, Sabbas A, Pavese A, Trichter S, Nedialkova L, Parashar B, Nori D, Chao KS, Wernicke A. Radiation exposure and safety precautions following 131Cs brachytherapy in patients with brain tumors. Health Phys. 2017;112:403–8.

    Article  CAS  PubMed  Google Scholar 

  69. Wernicke AG, Smith AW, Taube S, Yondorf MZ, Parashar B, Trichter S, Nedialkova L, Sabbas A, Christos P, Ramakrishna R, Pannullo SC, Stieg PE, Schwartz TH. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J Neurosurg. 2017 Apr;126(4):1212–9.

    Article  CAS  PubMed  Google Scholar 

  70. Han DY, Ma L, Braunstein S, Raleigh D, Sneed PK, McDermott M. Resection cavity contraction effects in the use of radioactive sources (I-125 versus Cs-131) for intra-operative brain implants. Cureus. 2018;10(1):e2079.

    Google Scholar 

  71. Hirschfeld CB, Schwartz TH, Parashar B, Wernicke AG. Seed migration to the spinal canal after postresection brachytherapy to treat a large brain metastasis. Brachytherapy. 2016;15(5):637–41.

    Article  PubMed  Google Scholar 

  72. Brahimaj B, Lamba M, Breneman JC, Warnick RE. Iodine-125 seed migration within brain parenchyma after brachytherapy for brain metastasis: case report. J Neurosurg. 2016;125:1–4.

    Article  Google Scholar 

  73. Larson DA, Suplica JM, Chang SM, et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2004;6:119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Butler WM. Counterpoint: Cesium-131: not ready for prime time. Brachytherapy. 2009;8:4–6; discussion 7.

    Article  PubMed  Google Scholar 

  75. Ruge MI, et al. Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases. J Neurooncol. 2011;105:109–18.

    Article  PubMed  Google Scholar 

  76. Khan FM, Gibbons JP. Khan’s the physics of radiation therapy. Philadelphia: Lippincott Williams and Wilkins; 2014. p. 310.

    Google Scholar 

  77. Kehwar TS. Use of Cesium-131 radioactive seeds in prostate permanent implants. J Med Phys. 2009;34:191–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys. 2012;102:271–91.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, NewYork-Presbyterian/Weill Cornell Medicine, New York, NY, USA

    A. Gabriella Wernicke & Sean S. Mahase

  2. Department of Neurological Surgery, NewYork-Presbyterian/Weill Cornell Medicine, New York, NY, USA

    Theodore H. Schwartz

Authors
  1. A. Gabriella Wernicke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean S. Mahase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Theodore H. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodore H. Schwartz .

Editor information

Editors and Affiliations

  1. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, Director - Brain Metastases Program, New York, NY, USA

    Rohan Ramakrishna

  2. Department of Neurology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Rajiv S. Magge

  3. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Ali A. Baaj

  4. Department of Radiation Oncology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Jonathan P.S. Knisely

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wernicke, A.G., Mahase, S.S., Schwartz, T.H. (2020). Intraoperative Brachytherapy for Resected Brain Metastases. In: Ramakrishna, R., Magge, R., Baaj, A., Knisely, J. (eds) Central Nervous System Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-42958-4_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42958-4_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42957-7

  • Online ISBN: 978-3-030-42958-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation